<DOC>
	<DOCNO>NCT02912754</DOCNO>
	<brief_summary>This study involve add kinase inhibitor Ruxolitinib Ibrutinib treat Chronic Lymphocytic Leukemia ( CLL ) .</brief_summary>
	<brief_title>Ruxolitinib Combined With Ibrutinib Chronic Lymphocytic Leukemia Patients</brief_title>
	<detailed_description>Ibrutinib effective drug extend live CLL patient curative single agent may eventually select aggressive disease . Survival CLL cell presence Ibrutinib may enable signal microenvironment leukemia cell originate . These signal transmit cell Janus Kinases ( JAKs ) janus kinase 1 ( JAK1 ) janus kinase 2 ( JAK2 ) . According , JAK inhibitor may overcome cytoprotective property CLL microenvironment help improve outcome Ibrutinib . The JAK2 inhibitor Ruxolitinib license use myelofibrosis polycythemia rubra vera toxicity efficacy single agent CLL study two previous clinical trial . As single agent , Ruxolitinib inferior Ibrutinib . However , Ruxolitinib show cooperate Ibrutinib increase kill CLL cell vitro . Based observation , hypothesize Ruxolitinib significantly improve therapeutic efficacy single-agent Ibrutinib . This single center phase I/II trial determine efficacy safety ruxolitinib tablet CLL patient treat progression Ibrutinib consider risk progress basis persistent lymphocytosis lymphadenopathy 1 year Ibrutinib elevate beta-2-microglobulin ( b2M ) level 6 month Ibrutinib . Ruxolitinib administer 21 day 35-day cycle repeat 6 time .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<criteria>1 . Diagnosis CLL meeting publish diagnostic criterion . 2 . CLL currently treat Ibrutinib due relapsed/refractory disease primary del17p cytogenetic lesion daily dose 420 mg : failure plasma b2M level decrease 2.5 mg/L 6 month start Ibrutinib . persistent lymphocytosis ( &gt; 5x106 cells/L ) splenomegaly lymphadenopathy ( marker node &gt; 1.5 cm CT scan ) 1 year take Ibrutinib . 3 . Not currently treat agent CLL . 4 . Serum bilirubin , alanine transferase less equal twice upper limit normal . 5 . Platelets &gt; 75x109/L . Absolute neutrophil count ( ANC ) &gt; .75x109/L . Hemoglobin great equal 65 g/L 6 . Age &gt; 18 year old 7 . Eastern Cooperative Oncology Group ( ECOG ) &lt; 2 1 . Patients inadequate bone marrow reserve baseline visit demonstrate least one following : a. ANC &lt; .75x109/L b. platelet &lt; 75x109/L without assistance growth factor , thrombopoietic factor , platelet transfusion . C. hemoglobin &lt; 65 g/L despite transfusion . 2 . Patients progressive multifocal leukoencephalopathy ( PML ) . 3 . Patients clinically significant bacterial , fungal , parasitic viral infection , require therapy . Patients acute bacterial infection require antibiotic use delay screening/enrollment course antibiotic therapy complete . 4 . Patients know active hepatitis A , B , C HIVpositive risk hepatitis B virus ( HBV ) reactivation . At risk HBV reactivation define hepatitis B surface antigen positive antihepatitis B core antibody positive . Prior test result obtain part standard care prior alloSCT confirm subject immune risk reactivation ( ie , hepatitis B surface antigen negative , surface antibody positive ) may use purpose eligibility test need repeat . Subjects prior positive serology result must negative polymerase chain reaction result . Subjects whose immune status unknown uncertain must result confirm immune status enrollment . 5 . Primary immunodeficiency Xlinked agammaglobulinemia common variable immunodeficiency . 6 . Patients active inactive ( 'latent ' ) tuberculosis infection . 7 . Involvement central nervous system lymphoma leukemia . 8 . Richter 's transformation prolymphocytic leukemia . 9 . Uncontrolled autoimmune hemolytic anemia idiopathic thrombocytopenia purpura . 10 . Use glucocorticoids equivalent 10 mg prednisone daily within 4 week prior treatment . 11 . Major surgery within 4 week prior treatment . 12 . Patients history malignancy past 3 year except treat , earlystage squamous basal cell carcinoma . 13 . History current diagnosis uncontrolled significant cardiac disease , include follow : a. myocardial infarction within last 6 month . b. uncontrolled congestive heart failure . c. unstable angina within last 6 month . d. exertional angina . e. clinically significant ( symptomatic ) cardiac arrhythmia ( eg . bradyarrhythmias , sustain ventricular tachycardia , clinically significant second third degree block without pacemaker ) . 14 . History stroke intracranial hemorrhage within 6 month prior enrollment . 15 . Renal failure require dialysis serum creatinine &gt; 176.8 microM patient moderate ( creatinine clearance 3050 ml/min ) severe ( creatinine clearance &lt; 30 ml/min ) renal impairment platelet count less 100,000/ml . 16 . Patients mild , moderate , severe hepatic impairment inadequate liver function define direct bilirubin , alanine amino transferase ( ALT ) , aspartate aminotransferase ( AST ) &gt; 2.5 x upper limit normal ( ULN ) . 17 . Impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption oral ruxolitinib ( e.g. , ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome , small bowel resection ) . 18 . Patients know hypersensitivity ruxolitinib JAK1/2 inhibitor , excipients . 19 . Patients ongoing treatment another investigational medication treat investigational medication within 30 day screen 5 halflives ( whichever longer ) prior first dose study drug . 20 . Significant concurrent , uncontrolled medical condition , investigator 's opinion , would jeopardize safety patient compliance protocol . 21 . Subjects unable comprehend unwilling sign inform consent form ( ICF ) . 22 . Sexually active male agree use condom intercourse take ruxolitinib 3 month stop treatment ( N.B . mean elimination halflife ruxolitinib around 3 hour ) father child period . Vasectomized men must also agree use condom intercourse prevent delivery ruxolitinib via seminal fluid . 23 . Pregnant nursing ( lactate ) woman , pregnancy define state female conception termination gestation , confirm positive human choriogonadotropin ( HCG ) laboratory test ( &gt; 5 mIU/ml ) . 24 . Women childbearing potential , defined woman physiologically capable become pregnant , unless use highly effective method contraception throughout study duration inclusive 30 day safety follow . Highly effective contraception method include : Total abstinence ( line prefer usual lifestyle subject ) . Periodic abstinence ( e.g. , calendar , ovulation , symptothermal , postovulation method ) withdrawal acceptable method contraception Female sterilization ( surgical bilateral oophorectomy without hysterectomy ) , total hysterectomy tubal ligation least six week take study treatment . Incase oophorectomy alone , reproductive status woman confirm follow hormone level assessment Male sterilization ( least 6 month prior screen ) . vasectomize male partner sole partner subject . Use oral , injected implant hormonal method contraception placement intrauterine device ( IUD ) intrauterine system ( IUS ) form hormonal contraception comparable efficacy ( failure rate &lt; 1 % ) , example hormone vaginal ring transdermal hormone contraception Women consider postmenopausal child bear potential 12 month natural ( spontaneous ) amenorrhea appropriate clinical profile ( e.g . age appropriate , history vasomotor symptom ) surgical bilateral oophorectomy ( without hysterectomy ) , total hysterectomy tubal ligation least six week ago . In case oophorectomy alone , reproductive status woman confirm follow hormone level assessment consider child bear potential . 25 . Use strong CYP3A4 inhibitor patient phase I component trial .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>